An active second dihydrofolate reductase enzyme is not a feature of rat and mouse, but they do have activity in their mitochondria  by Hughes, Linda et al.
FEBS Letters 589 (2015) 1855–1862journal homepage: www.FEBSLetters .orgAn active second dihydrofolate reductase enzyme is not a feature of rat
and mouse, but they do have activity in their mitochondriahttp://dx.doi.org/10.1016/j.febslet.2015.05.017
0014-5793/ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: DHFR, dihydrofolate reductase; OCM, one carbon metabolism
Author Contributions: APMcD and MJOC designed the study. LH carried out all the
mitochondrial puriﬁcations, enzyme assays, Western blots, RT-qPCR and Sanger
sequencing. MJOC and RC designed and carried out the phylogenetic analyses. SM
designed PCR assays and performed rat gene sequence analysis. GM generated a
recombinant DNA clone. EED performed rat sequence analysis in wild species.
APMcD performed sequence analysis of gene duplicates. All authors contributed to
the drafting of this manuscript.
⇑ Corresponding author. Fax: +353 7005142.
E-mail address: anne.parle-mcdermott@dcu.ie (A. Parle-McDermott).Linda Hughes a, Robert Carton b,c, Stefano Minguzzi a, Gráinne McEntee a, Eva E. Deinumd,
Mary J. O’Connell b,c, Anne Parle-McDermott a,⇑
aNutritional Genomics Group, School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
bBioinformatics and Molecular Evolution Group, School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
cCentre for Scientiﬁc Computing and Complex Systems Modelling (SCI-SYM), Dublin City University, Glasnevin, Dublin 9, Ireland
d Institute of Evolutionary Biology, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, United Kingdom
a r t i c l e i n f o a b s t r a c tArticle history:
Received 2 April 2015
Revised 6 May 2015
Accepted 7 May 2015
Available online 14 May 2015
Edited by Takashi Gojobori
Keywords:
Dihydrofolate reductase
Rat
Mouse
Mitochondria
Folic acid
R. rattus
R. norvegicusThe identiﬁcation of a second functional dihydrofolate reductase enzyme in humans, DHFRL1, led us
to consider whether this is also a feature of rodents. We demonstrate that dihydrofolate reductase
activity is also a feature of the mitochondria in both rat and mouse but this is not due to a second
enzyme. While our phylogenetic analysis revealed that RNA-mediated DHFR duplication events did
occur across the mammal tree, the duplicates in brown rat and mouse are likely to be processed
pseudogenes. Humans have evolved the need for two separate enzymes while laboratory rats and
mice have just one.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Dihydrofolate reductase (DHFR) is an enzyme from the folate
one-carbon metabolism (OCM) pathway that has been extensively
studied due to its relevance as a clinical drug target [1], in drug
resistance [2,3] and in reducing the synthetic supplement folic acid
and 7,8 dihydrofolate to the active form, tetrahydrofolate [4].
Despite its popularity, it has only relatively recently been realised
that humans have acquired two dihydrofolate reductase enzymes
during their evolution, DHFR and DHFRL1 [5,6]. This appears tofulﬁll the requirements of recycling dihydrofolate to tetrahydrofo-
late in support of de novo Thymidylate synthesis at the nuclear and
mitochondrial genomes [6–8]. While it is clear that humans, and
likely all primates, have two functional DHFR enzymes encoded
by separate genes, the question remained whether non-primate
species followed a similar pattern. This is especially relevant
given the extensive utilisation of both rat and mouse models across
a plethora of biomedical research over many years [9]. Indeed,
many of the earlier research in relation to folate OCM was
based on the isolation of speciﬁc folate enzyme activities from
rat liver [10].
Given the central role of rodents in biomedical research and the
importance of antifolate drugs as therapeutics for human disease, a
full understanding of the commonalities and the more subtle
differences in OCM between rodents and humans is vital to ensure
the success of future/current therapeutics and nutritional supple-
ments. Bailey and Ayling [11] previously highlighted the dramatic
differences in the activity of endogenous human DHFR compared
to its counterpart in the rat. DHFR activity in human liver showed
wide variability between individuals and was ‘‘extremely slow’’ in
reducing folic acid to tetrahydrofolate compared to rat liver [11].
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as both a supplement and as part of mandatory (and voluntary)
fortiﬁcation programs to prevent neural tube defects [12]. The
detection of unmetabolised folic acid in the human circulation
[13,14] and the poor handling of folic acid by the human gut
[15], underscores the importance of understanding DHFR activity
across species and shedding light on the underlying reason(s) for
such differences.
We have used a combination of phylogenetic analysis,
sequence analysis, RT-qPCR, enzyme activity assays and
Western blotting in liver tissue and/or cell lines of mouse and
rat to address whether these species have DHFR activity in their
mitochondria and whether such activity is attributable to a sec-
ond functional DHFR enzyme, mirroring what we and others have
previously identiﬁed in humans [5,6]. We show that while both
rat and mouse do have DHFR activity in their mitochondria, we
rule out that activity being due to a second DHFR enzyme in
mouse and in the brown rat species Rattus norvegicus. We show
that brown rat and mouse DHFR, not only localises to the cyto-
plasm, as previously known, but also localises to the mitochon-
dria. While humans have evolved the need for two functional
DHFR enzymes, mice and brown rats have just one. This data
demonstrates a fundamental difference between humans and
our favoured animal models and should be considered in future
research in this area.
2. Materials and methods
2.1. Mitochondria extraction and puriﬁcation
Four T75 ﬂasks of NRK (normal rat kidney) and 4T1 (mouse
mammary tumour) cell lines were grown in DMEM (Sigma) sup-
plemented with 2 mM L-glutamine and FBS (Fetal Bovine Serum)
(10% NRK, 5% 4T1) until 80% conﬂuent. Cells were trypsinised
and the resulting pellets washed in PBS (Phosphate Buffered
Saline). The pellets from four ﬂasks were combined and the
mitochondria extracted using the Qproteome Mitochondria
Isolation kit (Qiagen) as per kit protocol with the following
adaptations: pellets were lysed using 1 ml of lysis buffer.
Disruption was completed using 500 ll of disruption buffer, a
1 ml syringe and a 27-gauge needle. The ﬁnal mitochondrial pellet
was resuspended in 100 ll of mitochondrial storage buffer.
Extraction from rat and mouse tissues were also carried out with
Qproteome Mitochondria Isolation kit (Qiagen) similar to the cell
line extractions except 240 mg of fresh tissue was minced with a
scalpel and placed in 1 ml of lysis buffer and homogenised using
the Ultra-turrax homogenizer, then a further 500 ll of lysis buffer
was added, all remaining steps were as per Qiagen protocol
and ﬁnal mitochondrial pellet was resuspended in 200 ll of
mitochondrial storage buffer.
2.2. DHFR enzyme activity assays
Endogenous enzyme activity was analysed using a
Dihydrofolate Assay Kit (Sigma cat. No. CS03040-1KT). The assay
was performed at room temperature and at pH 7.5 according to
the manufacturer’s instructions. Each reaction contained 100 lg
of total mitochondrial protein combined with kit reagents as per
the manufacturer’s protocol up to a ﬁnal volume of 500 ll in a
1 ml UVette. The absorbance was read every 15 s for 3.5 min at
340 nm using the reaction rate mode on the Biochrom Libra S12
UV/Vis spectrophotometer. Each assay was repeated with the
addition of 40 nM Methotrexate to inhibit reductase activity
thereby allowing deduction of background activity of reactions
that also consume NADPH. The delta OD of each reaction was
calculated from the linear portion of the graph.2.3. Western blot analysis
Following denaturation of samples at 95 C in loading buffer, a
volume of 18 ll of total protein from the mitochondrial extraction
(both cytoplasmic and mitochondrial fractions) were loaded onto
4–20% Precise Tris–glycine gels (Thermo Scientiﬁc) and run at
100 V in Tris–glycine SDS running buffer. Proteins were transferred
onto PVDF membrane using the Pierce G2 Fast Blotter System
(Thermo Scientiﬁc) and blocked in 5% non-fat milk for 2 h. Blots
were probed with 1/5000 Anti-DHFR antibody produced in rabbit
(Abcam ab124814) and 1/1000 Anti-GAPDH and Anti-PDH anti-
body produced in mouse (Sigma G8795) and incubated overnight
at 4 C with gentle rocking. Blots were washed in TBST (Tris
Buffered Saline with Tween) and probed with appropriate sec-
ondary antibodies at 1/50,000 dilution. Blots were imaged using
Super Signal West Femto Max Sensitivity substrate (Thermo
Scientiﬁc 34095) and the Syngene bioimaging system.
2.4. Phylogenetic analysis of DHFRLS in other species
The query sequences for our whole genome searches
were extracted as canonical transcripts from the Ensembl
database [16]: human DHFR (ENST00000439211), mouse DHFR
(ENSMUST00000022218), rat DHFR (ENSRNOT00000018259),
human DHFRL1 (ENST00000394221), putative rat DHFRLS (chromo-
some 4: 414,175–414,721), human DHFRP2 (ENSG00000228432).
Using these sequences as queries we searched both the Ensembl
database [16], Genbank (www.ncbi.nlm.nih.gov/genbank/) and
the NCBI EST database (www.ncbi.nlm.nih.gov/dbEST/). The
Chinese Hamster genome was also used for closer examination of
the rodent clade [17]. The phylogenetic tree used in the study is
well resolved [18,19]. The completed genomes used ranged in
quality from 1.85X coverage to very high coverage (>6X). These
genomes were selected based on their phylogenetic distribution,
as we sought to examine the presence or absence of gene dupli-
cates from early vertebrate evolution right through to the diver-
gence of rodents and primates. To aid in the classiﬁcation of a
homologue as either the DHFR gene or a duplicate (pseudogene
or other), we examined the syntenic location of all genes, putative
duplicates and pseudogenes for all species in our dataset. Our
dataset consisted of vertebrate genomes from Ensembl Genome
Browser release 64 and the Chinese hamster genome [16,17]. A
gene was deemed a putative duplicate if it had a sequence similar-
ity score of 80% or higher in comparison to the DHFR transcript, an
E-value <1030 and a sequence length >300 bp. The majority of
subject sequences found had an E-value lower than 10150. To
differentiate between putative duplicates we examined the
syntenic information for each region. Duplicate genes that satisﬁed
the sequence similarity criteria and that had conserved synteny
across species were deemed homologous. Any putative duplicate
sequence that met the strict similarity criteria outlined above,
and following synteny analysis could be conﬁrmed as unique from
all previously identiﬁed DHFR pseudogenes, was classiﬁed as a
DHFR-like sequence, or DHFRLS.
2.5. Sequence analysis of gene duplicates
The region containing mouse DHFRLS was retrieved from
Ensembl (http://www.ensembl.org/index.html) GRCm38, chromo-
some 9: 31567433:31568480. Rat DHFRLS on chromosome 4 was
retrieved from Ensembl Rat genome versions RGSC Rnor_5.0
(DHFRLS ORF 4: 3139757–3140178) and RGSC 3.4 (DHFRLS is
within the following region, 4: 413244–415704). ORF Finder
was used to search for open reading frames in all 6 frames in
both mouse and rat DHFRLS. Sequence alignments were performed
at http://www.ebi.ac.uk/Tools/msa/clustalw2/. A speciﬁc DNA
Table 1
DHFR activity in rat and mouse mitochondria.
Tissue/cell linea Cytoplasm SAb (nmol/min/
mg)
Mitochondria SAb (nmol/
min/mg)
Rat liver 7.15 6.04
Rat kidney 7.4 9.37
Mouse liver n.dc 5.0
Mouse cancer
line
5.39 44.0
a All extracts were tested for purity of mitochondria by Western blot with both
rat liver and kidney shown in Fig. 4(B) and mouse cancer line in Fig. 1.
Mitochondrial purity of mouse liver was also demonstrated by Western blot (data
not shown).
b SA = speciﬁc activity per mg of mitochondrial preparation weight.
c n.d. = Not determined.
Fig. 1. Purity of mitochondrial extracts in Rat and Mouse. A representative Western
blot of rat and mouse mitochondrial extracts probed with the cytoplasmic marker
(GAPDH) showing purity of the mitochondrial extraction protocol. Lane order: 1:
SDS PAGE ruler, 2: rat cell line cytoplasm (21.4 lg protein loaded), 3: rat cell line
mitochondria (32.4 lg protein loaded), 4: mouse cancer line cytoplasm (33.1 lg
protein loaded), 5: mouse cancer line mitochondria (42.1 lg protein loaded). Every
mitochondrial preparation used in this study (including enzyme activity measure-
ments) was conﬁrmed for purity by Western blot.
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Bioscience) of PCR products ampliﬁed using the following
primers: Forward 50 GAAAAATCAACCTTTAAAGGATAG 30; Reverse
50 AATAAATTTTAAAACATCATCCAGAC 30 and template genomic
DNA extracted from the livers of two different Sprague Dawley rats
using the DNeasy Blood and Tissue kit (Qiagen).
2.6. Reverse transcribed-quantitative PCR
RNA was extracted from normal rat kidney (NRK) cells using the
Isolate II RNA mini kit from Bioline as per the kit protocol and
DNAse treated using the AMPD1 kit from Sigma–Aldrich. Samples
were reverse transcribed to cDNA in two steps, 1 lg of DNAse
treated RNA was added to 2 ll of random hexamers primer mix
(50 ng/ll Bioline) and 4 ll Oligo (dT) 18 primer mix (50 lM
Bioline) heated at 70 C for 5 min then incubated on ice for
1 min. A master mix containing 4 ll of 5 Reaction Buffer
(Bioline), 1 ll Ribonuclease Inhibitor human (Sigma–Aldrich),
1 ll Bioscript Reverse Transcriptase (200 U/ll Bioline), 1 ll
10 mM dNTPs (Sigma–Aldrich) and 1.5 ll Nuclease Free H2O per
sample, was added to each sample and they were placed on the
thermocycler using the following protocol 25 C  10 min,
42 C  60 min, 70 C  15 min then held at 4 C. Gene speciﬁc
assays for DHFR and Ywhaz assays were designed using the
Universal Probe Library (UPL) from Roche and the DHFRLS assay
was hand designed to ensure primers would not amplify DHFR
and the probe was designed using guidelines from IDT. Each
RT-qPCR reaction contained 1 ll cDNA, 0.16 ll UPL probe, 0.2 lm
forward and reverse primer, 8 ll of Sensimix™ II Probe Kit
(Bioline) and was made up to a ﬁnal volume of 15 ll with nuclease
free water. All assays and analysis were performed on the Roche
Lightcycler 480 using the following conditions: 5 min
pre-incubation at 95 C, ampliﬁcation 45 cycles of 30 s at 95 C,
30 s at 60 C and 1 s at 72 C. Primers and probes used are as fol-
lows: DHFR primers: Forward 50 AAAGTGGACATGGTCTGGGTA 30;
Reverse 50 CTGGCTGATTCATGGCTTC 30; Universal Probe #16.
Ywhaz Primers: Forward 50 CTACCGCTACTTGGCTGAGG 30;
Reverse 50 TGTGACTGGTCCACAATTCC 30; Universal Probe #9.
DHFRLS RT-qPCR primers are described in Supp. Fig. 1.
2.7. Rat sequence analysis in wild species
The region containing the frameshifted DHFRLS on RGSC
Rnor_5.0 Chromosome 4: 3139757–3140178 was compared to
the equivalent region in 12 wild brown rats (R. norvegicus) and 1
wild black rat (Rattus rattus) as follows: high depth Illumina
sequence reads from 12 R. norvegicus individuals sampled from
N.W. China [20] and a single R. rattus individual were aligned to
the R. norvegicus reference genome version Rnor_5.0. The relevant
region (chr4: 3139757–3140178) was extracted from raw bam
ﬁles using (the Genome Analysis Toolkit (GATK) [21] uniﬁed geno-
typer with the following options – output_mode EMIT_ALL_SITES
and genotype_likelihoods_model BOTH to retain maximum infor-
mation. Throughout the region, the coverage of the R. rattus sample
was close to the modal coverage for the genome as a whole (33X).
The R. rattus sequence was called homozygous at all sites and all
substitutions were supported by all or all but one read. The R. rat-
tus contained a 2 bp deletion of bases 3,139,975-6, which was sup-
ported by 34 of 35 reads. The twelve R. norvegicus samples all had
coverage close to their respective sample modes of 19–46X. All
samples were called homozygous reference at all sites, with the
sole exception of sample R10 (ERS215798), which was heterozy-
gous for a C? T transition at position 3,139,847 (12 reads C, 9
reads T), part of a CpG dinucleotide.3. Results
3.1. Rat and mouse possess dihydrofolate reductase activity in their
mitochondria
Puriﬁed mitochondria from rat and mouse tissues (liver and/or
kidney) or a mouse cell line were assessed for dihydrofolate reduc-
tase activity in light of what had been previously observed in
human [5,6]. Cytoplasmic and mitochondrial fractions were puri-
ﬁed from a rat NRK and mouse 4T1 cell line respectively. The same
fractions were also puriﬁed from rat liver and kidney tissue and
mouse liver tissue. A high level of reductase enzyme activity was
detected in the cytoplasmic fraction as expected. We also observed
reductase activity in the puriﬁed mitochondria in both rat and
mouse (Table 1). It was essential that we demonstrated that our
mitochondrial fractions were not contaminated with cytoplasm
as the cytoplasm contains a very high level of Dhfr enzyme nor-
mally and mitochondrial extracts, can be frequently contaminated
with cytoplasm if not executed carefully. Conﬁrmation that the
mitochondrial fractions were free from contamination with the
cytoplasm was shown by Western blot (Fig. 1). This analysis
demonstrated that dihydrofolate reductase activity is also a feature
of the mitochondria in both rat and mouse.
3.2. Examination of DHFR gene duplication events across the
vertebrate tree
The possibility that non-human species also possess a second
intact Dihydrofolate Reductase-Like sequence (DHFRLS) was
explored by a phylogenetic analysis. This analysis demonstrated
that a number of DNA mediated and RNA mediated duplication
events occurred across the vertebrate tree. Representatives from
all major clades of mammals, as well as outgroup species from
1858 L. Hughes et al. / FEBS Letters 589 (2015) 1855–1862the Aves and Teleostii clades, were examined for the presence of
DHFRLS. Fig. 2 shows all species tested in this analysis and their
phylogenetic relationships as currently understood and
summarises the distribution of DHFRLS identiﬁed [18,19]. It is clear
that there is a wide phylogenetic distribution of duplicates of the
DHFR gene across the mammalia, with the exception of the
afrotheria (represented by Hyrax, Elephant and Tenrec) and
monotremata (represented by Platypus) (although this may be
due to sequence quality for these genomes rather than genuine
absence from these genomes). All of the DHFRLSs identiﬁed are
intronless and are most likely the result of RNA mediated
duplication, i.e., retrotransposition events. We found no evidence
of DHFR retrotransposition outside of the mammal clade. We also
determined if there was evidence for DNA mediated duplication in
the Aves and Teleostii. We tested for the presence of DHFR
paralogs using the coding DNA sequence (CDS) of the native copy
of DHFR for each species of Aves and Teleostii and by searching each
exon individually. The only signiﬁcant result for both the
DHFR CDS search and the exon search was the DHFR
gene itself – indicating that there are no traceable functional
duplicates of DHFR outside of the mammals. Although the
phylogenetic analysis identiﬁed a DHFRLS in a number of mammal
species, further sequence analysis was required to assess whether
they contained an intact open reading frame (ORF) and were
capable of encoding a full length dihydrofolate reductase-like
enzyme.Fig. 2. Phylogenetic distribution of the DHFR genes/pseudogenes across the vertebrata. Th
a table representing the genome coverage and presence of DHFR and DHFRLSs. DHFR:
dihydrofolate reductase pseudogene 2, DHFRL1: dihydrofolate reductase like 1, DHFRLS
classiﬁed as: ‘‘P’’ gene present and annotated; ‘‘G’’ gene present but unannotated; ‘‘U’’ un
these classiﬁcations are preceded by a number that depicts the number of copies in tha3.3. Sequence analysis identiﬁes a putative functional DHFRLS in rat
but not in mouse
We focused our attention on the mouse and rat genomes
given their widespread utilisation as animal models in research.
The DHFRLS identiﬁed on chromosome 9 of the Ensembl Mouse
genome (chromosome 9: 31,375,437–31,375,758) was assessed
for ORF content using ORF ﬁnder. Despite sharing approxi-
mately 80% sequence identity with the CDS of its parent
DHFR, this sequence does not encode an intact dihydrofolate
reductase ORF. Our ﬁrst analysis of the Ensembl Rat genome
was performed on the most updated version available, the Rat
RGSC3.4 assembly. It identiﬁed a putative un-annotated
DHFRLS on chromosome 4 (chromosome 4: 414,206–414629).
The predicted ORF of the putative DHFRLS was a shortened ver-
sion of its equivalent parental DHFR but contained all the
domains required for reductase activity as deﬁned by PRINTS
(www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/). We next
sought to test whether this putative rat DHFRLS was actually
expressed.
3.4. RT-qPCR analysis shows no evidence of expression of the DHFRLS
in rat
An RT-qPCR assay was carefully designed to ensure speciﬁc
ampliﬁcation of the rat DHFRLS and not its parental homologuee phylogeny of the taxa sampled in this study is shown on the left and on the right is
dihydrofolate reductase, DHFRP1: dihydrofolate reductase pseudogene 1, DHFRP2:
: dihydrofolate reductase like sequence. The sequence similarity search results are
-annotated genomic sequence; or ‘‘?’’ no sequence identiﬁed. In the DHFRLS column
t category, the absence of a numeric value indicates a single copy in that category.
L. Hughes et al. / FEBS Letters 589 (2015) 1855–1862 1859(Supp. Fig. 1). Steps were also taken to ensure that any ampliﬁed
RT-PCR product arose from reverse transcribed mRNA and not
from contaminating genomic DNA. This was particularly crucial
given the intronless nature of the putative DHFRLS. Our RT-qPCR
data of the putative DHFRLS showed no evidence of expression in
RNA isolated from rat liver from two separate rats, and the NRK cell
line (Fig. 3). We ruled out technical reasons contributing to this
result such as inefﬁcient cDNA synthesis or PCR efﬁciency.
Integrity of our cDNA was demonstrated by the detection of the
endogenous control gene Ywhaz [22] and parental Dhfr gene
expression by RT-qPCR. The efﬁciency of our DHFRLS PCR assay
was demonstrated using a serial dilution of a recombinant clone
of the putative sequence (Supp. Fig. 2). This data indicated that
although version RGSC3.4 of the rat genome contained a putative
rat DHFRLS, we could ﬁnd no evidence that it was an expressed
gene.
3.5. The source of mitochondrial DHFR activity is parental DHFR in rat
and mouse
The lack of an expressed and functional DHFRLS in either lab-
oratory brown rat or mouse indicated that the source of the
DHFR activity in the mitochondria in both species was in fact
the ‘original’ DHFR itself (mouse-chromosome 13;
rat-chromosome 2). We performed Western blot analysis of puri-
ﬁed mitochondria from rat and mouse cell lines (Fig. 4) and
demonstrate a clear 21kDa band with a DHFR speciﬁc antibody.
Cytoplasmic fractions from the same cells were included for
comparison and as a positive control. Again the purity of the
mitochondrial (and cytoplasmic) fractions was veriﬁed by PDH
(Pyruvate Dehydrogenase, mitochondrial marker) and GAPDH
(cytoplasmic marker). This analysis demonstrates for the ﬁrst
time that endogenous rat and mouse DHFR localises to the mito-
chondria in addition to the cytoplasm.Fig. 3. RT-qPCR shows no evidence of expression of a rat DHFRLS. RT-qPCR was carried o
and RNA extracted from a rat cell line (NRK). The speciﬁc genes analysed are described i
level i.e., the lower the Cp the higher the level of expression) is shown on the Y-axis. N
reasons for non-detection of expression of the DHFRLS were ruled out due to the succes
Ywhaz.3.6. Sequence analysis of the updated rat genome identiﬁes a frame-
shift in the rat DHFRLS
While our original sequence analysis of the putative rat DHFRLS
was based on the sequence retrieved from Rat genome version
RGSC3.4, we subsequently retrieved the equivalent region from
the updated version Rnor_5.0 released in 2013. An alignment of
putative DHFRLS from both versions of the rat genome showed
that version Rnor_5.0 had a single base deletion that essentially
knocks the putative DHFRLS out of frame (Supp. Fig. 3). We
Sanger sequenced a PCR product ampliﬁed from the region that
contained the single base deletion in DNA isolated from rat liver
of laboratory rat strain Sprague Dawley (Fig. 5). This conﬁrmed
that laboratory rat strains harbour a frameshift mutation that
abolishes the ORF of the putative DHFRLS. As described earlier,
we also found no evidence of expression of this putative DHFRLS
in lab rat cell lines or liver tissue. Unlike the mouse DHFRLS, which
possessed a range of base changes to extensively degrade the
reductase ORF, the lab rat DHFRLS appears to have acquired a
single base deletion to cause a non-sense frameshift. We thus,
hypothesised that the single base deletion may potentially be a
newly acquired mutational event and even be possibly a
polymorphism within the rat population or potentially unique to
laboratory rat strains.
3.7. DHFRLS in wild black rat has an intact open reading frame due to
a 2 bp deletion
Laboratory rat strains are R. norvegicus species and are more
commonly known as the brown rat or the Brown Norway rat
[23]. R. norvegicus was used to sequence the rat genome [23].
Their genus cousin is the black rat known as R. rattus [24]. To test
the hypothesis that the non-sense frameshift mutation in the lab-
oratory rat genome is polymorphic and/or unique to lab brown ratsut on mRNA isolated from two separate rat liver RNA extractions (rat liver A and B)
n the X-axis, while the Cp value (which inversely correlates with mRNA expression
o Cp value was detected for DHFRLS even at high cycle numbers i.e., 45. Technical
sful (and relatively early) ampliﬁcation of ‘parental’ DHFR and the rat control gene
Fig. 4. Detection of endogenous mitochondrial DHFR in mouse and rat by Western blot analysis. (A) Western blot of mitochondrial and cytoplasmic protein extracts showing
expression of endogenous reductase in rat (NRK) and mouse (4T1) cell lines probed with Anti-DHFR antibody: Lane order: 1: SDS PAGE ruler, 2: rat cell line cytoplasmic, 3: rat
cell line mitochondrial, 4: mouse cell line cytoplasmic, 5: mouse cell line mitochondrial after probing with DHFR antibody. The mitochondrial extracts were previously shown
to be free from contamination with cytoplasm as shown in Fig. 1. (B) Western blot of mitochondrial and cytoplasmic protein extracts showing DHFR enzyme present in both
cytoplasmic and mitochondrial extracts of rat liver and kidney tissue. The top panel shows the samples probed with Anti-DHFR antibody. The blot was stripped twice and
reprobed with Anti-GAPDH (middle panel) and Anti-PDH antibody (bottom panel). Mitochondria extracts are pure with no GAPDH detected, only PDH. The cytoplasm
fractions show some leakage from the mitochondria during extraction with faint bands of PDH but this is not a concern for this experiment (the lower bands are reminants of
the GAPDH signal as this was a stripped blot). Lane order: 1: SDS PAGE ruler, 2: rat 1 liver cytoplasm (29 lg protein loaded), 3: rat 2 liver cytoplasm (26.8 lg protein loaded),
4: rat 1 kidney cytoplasm (15.5 lg protein loaded), 5: rat 2 kidney cytoplasm (19.4 lg protein loaded); 6: DHFR recombinant protein (Sigma), 7: SDS PAGE ruler, 8: rat 1 liver
mitochondria (25.7 lg protein loaded), 9: rat 2 liver mitochondria (21.4 lg protein loaded), 10: rat 1 kidney mitochondria (10.3 lg protein loaded), 11: rat 2 kidney
mitochondria (6.8 lg protein loaded).
Fig. 5. Sanger sequencing conﬁrms version RGSC Rnor_5.0 of the rat genome has the correct version of the rat DHFRLS sequence on chromosome 4. (A) Sequence of putative
rat DHFRLS in version RGSC Rnor_5.0 of the rat genome. The underlined and bold ‘GG’ sequence highlights the site of discrepancy with RGSC 3.4 version i.e., ‘GGG’. This results
in a premature stop codon resulting in a shortened amino acid sequence of just 82 amino acids (see Supp. Fig. 3). (B) Sanger sequencing of PCR product ampliﬁed from
genomic DNA of a Sprague Dawley rat conﬁrms only two ‘G’ bases occur (RGSC Rnor_5.0) and not three (RGSC 3.4) as shown in the boxed portion of the chromatogram
(sequencing with the reverse primer is shown).
1860 L. Hughes et al. / FEBS Letters 589 (2015) 1855–1862we compared the rat DHFRLS on chromosome 4 (RGSC Rnor_5.0) to
a sequenced wild rat population consisting of 12 brown rats
(R. norvegicus) and 1 black rat (R. rattus). This analysis showed thatthe wild brown rat samples were similar to their lab brown rat
counterparts in that the DHFRLS also contains a non-sense reading
frame. This conﬁrms that both lab and wild brown rats do not
Fig. 6. Amino acid sequence alignment of the putative wild black rat DHFRLS with brown rat DHFR. The wild black (R. rattus) rat putative DHFRLS is labelled as ‘Rattus’ and
the brown rat (R. norvegicus) functional (or ‘parental’ NP_569084) DHFR is labelled as ‘DHFR’. Although the black rat DHFRLS is a shorter protein than the known functional rat
DHFR, it does contain all four domains that have previously been identiﬁed as being necessary for dihydrofolate reductase activity (highlighted in bold). It is unclear whether
this black rat DHFRLS is actually expressed.
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Interestingly, analysis of the single wild black rat indicates that
the equivalent DHFRLS in this genome contains a homozygous
2 bp deletion when compared to DHFRLS in brown rat. Analysis
of the possible ORF in this sequence region shows that wild black
rat contains an intact ORF. The ORF encodes a DHFRLS that is
shorter than functional rat DHFR sequence but does contain all
the domains required for dihydrofolate reductase activity (Fig. 6).
It is unclear whether this putative wild black rat DHFRLS is actually
expressed and produces an mRNA that is subsequently translated.
This needs to be veriﬁed experimentally through the isolation of
wild black rat RNA. While we cannot conﬁrm if wild black rat
DHFRLS is expressed, we can conﬁrm that it does possess the cod-
ing capacity to produce a second active dihydrofolate reductase
enzyme.
4. Discussion
We have demonstrated that dihydrofolate reductase activity is
also a feature of the mitochondria in both rat and
mouse (Table 1, Figs. 1 and 4), but this is not due to a second
reductase enzyme. While our phylogenetic analysis revealed that
RNA-mediated DHFR duplication events did occur across the
mammalian tree (Fig. 2), it appears that the duplicates in brown
rat and mouse are likely to be processed pseudogenes as they lack
the coding capacity for an intact reductase ORF and we found no
evidence of mRNA expression in lab rat tissue or in a rat cell line
(Fig. 3). While, the mouse DHFRLS had accumulated numerous
mutations to negate any possibility of a reductase ORF, the rat
DHFRLS tantalisingly had lost its reductase like ORF to a single base
shift. We showed that while both lab and wild brown rat lacked an
intact ORF, wild black rat retained a reductase like ORF that has the
potential to encode a second reductase enzyme (Fig. 6). If
expressed and functional, the wild black rat mirrors the human
DHFR scenario i.e., it also has two functional dihydrofolate reduc-
tase enzymes (albeit arising from separate gene duplication
events) and may provide clues as to the relevance of this for human
folate metabolism. The Rattus species is thought to have arisen in
South-East Asia with further divergence giving rise to 66
recognised species including R. rattus and R. norvegicus [24].
While R. rattus was believed to have arrived in Europe ﬁrst,
R. norvegicus outcompeted R. rattus in the more temperature
climates of Europe following their arrival during the 18th century
[20]. If R. rattus did have a second functional reductase, it could
potentially allow an interesting investigation of diet and habitat
differences between the two species and how this relates to folate
metabolism. However, conﬁrmation of expression in isolated
R. rattus RNA samples will be required to assess whether this is a
possible line of investigation.Human DHFR is known to localise to the cytoplasm and nucleus
[7,8] with its paralogue DHFRL1 localising to the mitochondria
[5,6]. While mitochondrial reductase activity has been detected
in CHO cells [6], rat and mouse have not been proven previously.
Interestingly, a publication from 1965 provided early evidence that
rat mitochondria did harbour DHFR activity [25], however further
investigation during this period failed to substantiate this ﬁnding
[26]. Our enzyme activity and Western blot data (Table 1, Figs. 1
and 4) clearly demonstrate that endogenous mouse and brown
rat DHFR co-localise to the cytoplasm and mitochondria. In con-
trast to humans, a single gene satisﬁes the dihydrofolate reductase
requirements in both brown rat and mouse. A question that
remains to be answered is why humans (and possible wild black
rats) retained their DHFR-like retrogene (DHFRL1) for speciﬁc
localisation to the mitochondria while other mammalian species
did not. The answer may lie in the reduced enzyme activity of
DHFRL1 [5] and its role in the mitochondria may extend beyond
that of a simple enzyme. Alternatively, the ‘on-site’ supply of
Thymidylate appears to be a feature of both the nuclear and mito-
chondrial genome and having the ability to differentially control
thymidylate production at either genome may be the underlying
selective advantage to having two rather than one DHFR enzyme.
Another advantage to having a second reductase in the mitochon-
dria might relate to its signiﬁcant oxidative stress environment and
the vulnerability of speciﬁc folate forms to oxidation. DHFRL1 may
be better suited to the alkaline environment of the mitochondria
and may slow the non-enzymatic oxidative loss of folate.
Our detailed analyses of the DHFR gene family in mammals
highlights once again our need for caution in relation to the utili-
sation of animal models to extrapolate to the human situation.
Although high proﬁle mishaps in translating from animal models
to clinical trials are rare [27], it does emphasise that attention to
the detail of the differences between animal models and humans
is warranted. Mouse and rat models are the cornerstone of a signif-
icant portion of in vivo research and will continue to remain so in
the foreseeable future. Apart from their use in the study of folate
metabolism, they are a central part of novel drug development
on the road to clinical trials [28]. DHFR itself has long been a drug
target [1] without any knowledge of the existence of DHFRL1 or
indeed that a dihydrofolate reductase activity was a feature of
mitochondria. Details such as these are crucial, particularly as it
is unlikely that anti-folate drugs transport efﬁciently into mito-
chondria as oxidised forms of folate appear to transport in slowly
[29], although of note, this was based on an investigation of rat
mitochondria. Our data provides clarity on one of the fundamental
differences between folate metabolism in humans and that of our
favoured animal models. A straight forward mouse or rat model
of DHFRL1 is not a possibility in light of our analyses and further
investigation of the human DHFRL1 enzyme will now be restricted
1862 L. Hughes et al. / FEBS Letters 589 (2015) 1855–1862to human (or potentially non-human primate) derived tissues
and/or cell lines. This data will inform future studies where animal
model data is being used to extrapolate to human studies and
demonstrates that closer attention needs to be paid to the intricate
differences between humans and rodents.
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